Physician profile
Carol E Powers
NPI 1649378738
$327,022.30
in general payments reported to CMS, 2019-2025
39 companies · $65K in 2025
The $65K reported for 2025 was more than what 99% of Obstetrics providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $9,238 · 2021: $38K · 2022: $51K · 2023: $70K · 2024: $70K · 2025: $65K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $125K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $56K · Food and Beverage: $13K · Travel and Lodging: $12K · Entertainment: $37.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $124,951.99 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $55,500.00 |
| Food and Beverage | $12,938.26 |
| Travel and Lodging | $11,792.66 |
| Entertainment | $37.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $318,661.58 | 2019-2025 | Da Vinci Surgical System, Da Vinci Sp |
| Coloplast Corp | $1,631.02 | 2019-2025 | Restorelle |
| Abbvie INC. | $1,354.80 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $656.49 | 2023-2025 | Myfembree |
| Myovant Sciences INC. | $509.00 | 2021-2022 | |
| Caldera Medical, INC | $415.90 | 2019-2024 | Desara |
| Astellas Pharma US INC | $373.02 | 2021-2025 | Veozah |
| Pfizer INC. | $259.82 | 2019-2025 | |
| Biogen, INC. | $259.07 | 2024-2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $256.42 | 2021-2024 | Aptima, Coolseal Generator, Novasure |
| Exeltis, USA INC. | $253.28 | 2020-2025 | Slynd |
| Aspira Women'S Health INC | $216.47 | 2020-2023 | Ova1 |
| Mayne Pharma Commercial LLC | $196.82 | 2021-2025 | |
| Organon LLC | $190.19 | 2021-2025 | Nexplanon, Jada System |
| Medtronic, INC. | $158.56 | 2021-2024 | V-Loc 180, Situate |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $148.49 | 2019-2025 | |
| Therapeuticsmd, INC. | $126.11 | 2019-2022 | |
| Conmed Corporation | $114.35 | 2023 | Airseal, Vcare |
| Bard Peripheral Vascular, INC. | $107.00 | 2022 | |
| Coopersurgical, INC. | $104.85 | 2020-2024 | Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $102.39 | 2020-2025 | |
| Medicem INC. | $99.92 | 2023 | |
| Femselect INC. | $93.55 | 2025 | Enplace |
| Smith+Nephew, INC. | $82.62 | 2021-2024 | Pico 7 |
| Millicent US INC | $77.80 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Allergan, INC. | $70.45 | 2019-2020 | |
| Agile Therapeutics, INC. | $67.11 | 2021-2024 | Twirla |
| Boston Scientific Corporation | $56.39 | 2019-2023 | Varithena Administration Pack |
| Vertex Pharmaceuticals Incorporated | $51.45 | 2025 | |
| Avion Pharmaceuticals | $50.79 | 2020-2023 | Balcoltra |
| Ascend Therapeutics US, LLC | $46.54 | 2022-2023 | |
| Shield Therapeutics INC | $45.21 | 2023-2024 | Accrufer |
| Mylan Pharmaceuticals INC. | $41.56 | 2021 | |
| Zyla Life Sciences, INC. | $37.49 | 2020 | |
| Amag Pharmaceuticals, INC. | $29.64 | 2019-2020 | |
| Channel Medsystems, INC. | $22.53 | 2025 | |
| Merck Sharp & Dohme LLC | $22.26 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $19.19 | 2020 | |
| Covidien Lp | $12.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.